Remove 2030 Remove Assay Development Remove Drug Development
article thumbnail

Six Factors for Biotech Companies to Consider When Choosing Next-Generation Contract GMP/CMC Laboratories

PPD

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. 1 With this growth comes increased demands for laboratory services at all steps across the development process. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.

article thumbnail

Early phase support for plasmid DNA supply to secure future manufacturing

Drug Discovery World

billion by 2030 (BioSpace, 11 August 2022). Plasmid DNA: a critical reagent pDNA is the starting material for the development of many cell and gene therapy products, irrespective of the mode of action. This rapid emergence of cell and gene therapies has fuelled demand for plasmids and has created a manufacturing ‘bottleneck’.

DNA 130
article thumbnail

Advances in cell line development

Drug Discovery World

Reece Armstrong offers an overview of cell line development and outlines the benefits the technology is bringing to biopharmaceutical developers. Cell line development is an essential underpinning of the drug development process, enabling teams to test, optimise and manufacture therapeutics at a commercial scale.

Vaccine 147